Synthetic inhibitors of thrombin and factor Xa: from bench to bedside (Q33540693)

27 July 2017

1 reference

title

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside (English)

1 reference

27 July 2017

2

Stürzebecher J

1 reference

27 July 2017

Hauptmann J

1

1 reference

27 July 2017

publication date

1 March 1999

1 reference

27 July 2017

1 reference

27 July 2017

volume

93

1 reference

27 July 2017

issue

5

1 reference

27 July 2017

page(s)

203-241

1 reference

Fibrinogen and fibrin--proteins with complex roles in hemostasis and thrombosis

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Thrombin active site inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Specific thrombin inhibitors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Pharmacologic Aspects of the Development of Selective Synthetic Thrombin Inhibitors as Anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

New thrombin inhibitors in cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

The refined 1.9-Å X-ray crystal structure of d-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on so

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Diarylsulfonamides as selective, non-peptidic thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Design and synthesis of potent and highly selective thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Inhibitor binding to thrombin: x-ray crystallographic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitutions

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Pharmacological characterization of a new 4-amidinophenyl-alanine thrombin-inhibitor (CRC 220).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Solid phase synthesis of benzylamine-derived sulfonamide library

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Solid phase synthesis of benzamidine-derived sulfonamide libraries

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

A comparison of heuristic search algorithms for molecular docking.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Retro-binding tripeptide thrombin active-site inhibitors: discovery, synthesis, and molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

New thrombin inhibitors based on D-cha-Pro-derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Structural modification of an orally active thrombin inhibitor, LB30057: replacement of the D-pocket-binding naphthyl moiety

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Proposed cation-pi mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Structure of human des(1-45) factor Xa at 2.2 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Mapping the active site of factor Xa by selective inhibitors: an NMR and MD study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Structural basis for chemical inhibition of human blood coagulation factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-am idino- 2- naphthyl)propanoic acid hydrochloride and some analogs to factor Xa using a comparative molecular field analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Synthetic inhibitors of bovine factor Xa and thrombin comparison of their anticoagulant efficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

(Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic Effects of Orally Active Synthetic Antagonist of Activated Factor X in Nonhuman Primates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

DX9065a, an Xa inhibitor, inhibits prothrombin-induced A549 lung adenocarcinoma cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor XA inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enz

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

A screening procedure to evaluate the anticoagulant activity and the kinetic behaviour of direct thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Characterization of the two-step pathway for inhibition of thrombin by alpha-ketoamide transition state analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Reaction of thrombin and proteinases of the fibrinolytic system with a mechanism-based inhibitor, 3,4-dihydro-3-benzyl-6-chloromethylcoumarin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Inhibition of the thrombin-platelet reactions by DuP 714

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Reproducibility and temporal stability of ADP-induced platelet aggregation: comparison of the anticoagulants sodium citrate and D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Local delivery of an antithrombin inhibits platelet-dependent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Adjuvant effect of argatroban on staphylokinase induced thrombolysis of platelet rich thrombi in rat mesenteric venules in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Degradation of a benzamidine-type synthetic inhibitor of coagulation enzymes in plasma of various species

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Local treatment with antithrombotic drugs can prevent thrombus formation: An angioscopic and angiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effects of locally administration of argatroban using a hydrogel-coated balloon catheter on intimal thickening induced by balloon injury

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effects of locally administered argatroban on restenosis after balloon angioplasty: experimental and clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine prepa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Contractile effects of thrombin in porcine pulmonary arteries and the influence of thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Endothelium-dependent relaxant effect of thrombocytin, a serine proteinase from Bothrops atrox snake venom, on isolated pig coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Inhibition of thrombin-induced endothelium-dependent relaxation after coronary ischemia in the dog: possible role of the coagulation cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Inhibitory Effect of Clopidogrel, Vapiprost and Argatroban on the Middle Cerebral Artery Thrombosis in the Rat

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Anti-thrombogenic effects of 2-hydroxyethylmethacrylate-styrene block copolymer and argatroban in synthetic small-caliber vascular grafts in a rabbit inferior vena cava model

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Development of a rapid and sensitive chromogenic heparin assay for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Quantitation of an orally available thrombin inhibitor in rat, monkey and human plasma and in human urine by high-performance liquid chromatography and fluorescent post-column derivatization of arginine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Combined administration of aspirin and a specific thrombin inhibitor in man

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Influence of indocyanine green on plasma disappearance and biliary excretion of a synthetic thrombin inhibitor of the 3-amidinophenyl-alanine piperazide-type in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Design of benzamidine-type inhibitors of factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Potent and selective thrombin inhibitors incorporating the constrained arginine mimic l-3-piperidyl(N-guanidino)alanine at P1.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Active site-directed thrombin inhibitors: α-hydroxyacylprolyl-arginals. New orally active stable analogs of d-Phe-Pro-Arg-H

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effect of argatroban on thrombus formation during acute coronary occlusion after balloon angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Effective anticoagulation by argatroban during immunoadsorption therapy for malignant rheumatoid arthritis with a high polymorphonuclear leukocyte elastase level

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Another chapter of the antithrombin story has been written...

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Challenges in the development of orally bioavailable thrombin active site inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Peptide boronic acid inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

Narrow-bore liquid chromatography-tandem mass spectrometry with simultaneous radioactivity monitoring for partially characterizing the biliary metabolites of an arginine fluoroalkyl ketone analog of D-MePhe-Pro-Arg, a potent thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2898%2900192-3

7 January 2021

10.1016/S0049-3848(98)00192-3

Identifiers

DOI

1 reference

27 July 2017

1 reference